CA
NZ
UK
AU
IND
US
Quince Therapeutics (NASDAQ:QNCX) has had one of the more difficult years a clinical-stage biotech can face: its pivotal trial failed, and the company moved to halt development of its lead program. Investors considering the shares should focus on what the company actually has left …
Aldeyra Therapeutics (NASDAQ:ALDX) has spent years navigating a winding regulatory path for its dry-eye-disease drug, and the story has reached another pivotal juncture. After earlier setbacks with the FDA, the company resubmitted its application for reproxalap, secured FDA acceptance for review, and expanded aPartnershipwith …
●Strong response data:Curis reported an 86% response rate in a BTK-inhibitor-naive lymphoma setting for emavusertib, its lead IRAK4 inhibitor.
FibroBiologics (NASDAQ:FBLG) is pursuing an unconventional idea in regenerative medicine: using fibroblasts, the common cells that build and maintain connective tissue, as the basis for cell therapies across a range of diseases. The company has been advancing its lead programs toward the clinic, and …
● The company's core is nicotinamide riboside (NR), a form of vitamin B3 marketed through Tru Niagen and a branded ingredient supplied to other companies.
● Outset reported second-quarter 2026Revenueof about $31.6 million in results that reporting described as mixed.
● The company lowered its full-year U.S. Omnipod outlook, citing challenges including retention among type 2 diabetes patients.
● The company reported second-quarter 2026 results in early August 2026 showing Auryxia sales declining while Vafseo gained traction.
BioAtla (NASDAQ:BCAB) has reached a difficult crossroads common to clinical-stage biotechs that run low on the market's patience and their own capital. The developer of conditionally active biologic therapies has launched a formal process to evaluate strategic options for monetizing its assets, a step …
DocGo (NASDAQ:DCGO) is working to reposition itself as a broader healthcare-services company. The mobile-health and medical-transportation provider reported second-quarter 2026 results that paired record patient volumes with a guidance cut, and it announced an acquisition intended to expand its virtual-care capabilities.
Please wait processing your request...